Structure-based development of anticancer drugs: Complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones

Structure

Volumn 9, Issue 8, 2001, Pages 659-667

  Faig, Margarita ^a   Bianchet, Mario A ^a   Winski, Shannon ^b   Hargreaves, Robert ^c   Moody, Christopher J ^d   Hudnott, Anna R ^d   Ross, David ^b   Amzel, L Mario ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIAZIRIDINYL 3 (HYDROXYMETHYL) 6 METHYL 1,4 BENZOQUINONE; 2,5 DIAZIRIDINYL 3 HYDROXYL 6 METHYL 1,4 BENZOQUINONE; 3 HYDROXYMETHYL 5 (2 METHYLAZIRIDIN 1 YL) 1 METHYL 2 PHENYLINDOLE 4,7 DIONE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; ARH 019; PRODRUG; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG ACTIVATION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME BINDING; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; GEOMETRY; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; KINETICS; MODELS, CHEMICAL; PROTEIN BINDING; QUINONE REDUCTASES; QUINONES; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 0034892645     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(01)00636-0     Document Type: Article

References (35)

1. Soluble diaphorase in animal tissues
2. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues
3. The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: Mechanism of the two-electron reduction
4. Structures of recombinant mouse and human NAD(P)H:quinone oxidoreductases: Species comparison and structural changes with substrate binding and release
5. Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse
6. Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: Combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling
7. Bioreductive activation of a series of indolequinones by human DT-diaphorase: Structure-activity relationships
8. Crystal structure of human DT-diaphorase: A model for interaction with the cytotoxic prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)
9. Treatment of patients with recurrent primary brain tumors with AZQ
10. Alteration in DNA cross-linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT-diaphorase
11. Cross-linking and sequence-specific alkylation of DNA by aziridinylquinones. 3. Effects of alkyl substituents
12. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): Role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells
13. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity
14. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies
15. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent
16. Nicotinamide adenine dinucleotide (phosphate): Quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones; quinone cytotoxicity and selectivity in human lung and breast cancer cell lines
17. The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9
18. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase
19. Indolequinone antitumor agents: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity
20. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): Implications for bioreductive drug development
21. Novel bioreductive anticancer agents based on indolequinones
22. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones
23. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: Study involving mouse, rat, human, and mouse-rat chimeric enzymes
24. Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in Escherichia coli and mutagenesis in vitro at Arg-177
25. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent
26. Processing of X-ray diffraction data collected in oscillation mode
27. 3D search and research using the cambridge structural database
28. Crystallography & NMR system: A new software suite for macromolecular structure determination
29. Improved methods for building protein models in electron density maps and the location of errors in these models
30. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities
31. RASTER3d
32. The CCP4 suite: Programs for protein crystallography
33. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons